A systematic review of contemporary phase I trials in patients with recurrent/metastatic head and neck cancer

Oral Oncology Reports Pub Date : 2024-07-04 DOI:10.1016/j.oor.2024.100588

V.G. Espeli , A. Gomez , P. Balermpas , G. Treglia , A. Stathis

{"title":"A systematic review of contemporary phase I trials in patients with recurrent/metastatic head and neck cancer","authors":"V.G. Espeli , A. Gomez , P. Balermpas , G. Treglia , A. Stathis","doi":"10.1016/j.oor.2024.100588","DOIUrl":null,"url":null,"abstract":"<div><p>We performed a systematic review of phase I trials specifically conducted for patients with head and neck squamous cell carcinoma published between January 1, 2008 and August 31, 2023. PubMed and Cochrane Library databases were searched using a combination of terms: “((head and neck) OR (head & neck)) AND ((cancer*) OR (tumor*) OR (tumour*) OR (neoplasm*) OR (carcinoma*) OR (malignan*)) AND ((phase 1) OR (phase I))\"to identify phase I dose-finding trials including a majority of lymphoma patients.</p><p>Eighty-five trials (H&N patients N = 1714) were included. Among them, 53 trials complying with inclusion/exclusion criteria and were included in the current analysis: 32 (60 %) enrolled only patients with head and neck cancer, while 21 (40 %) included also patients with other solid tumors.</p><p>The median rate of grade 3-4 adverse events was 41 %. With regards to clinical activity, the median response rate (RR) was 16 %, which is in line with the usually reported rate for phase I trials enrolling unselected populations of patients with solid tumors.</p></div>","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772906024004345/pdfft?md5=713aab26e897b0903c551dc4ebe6fd36&pid=1-s2.0-S2772906024004345-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oral Oncology Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2772906024004345","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

We performed a systematic review of phase I trials specifically conducted for patients with head and neck squamous cell carcinoma published between January 1, 2008 and August 31, 2023. PubMed and Cochrane Library databases were searched using a combination of terms: “((head and neck) OR (head & neck)) AND ((cancer*) OR (tumor*) OR (tumour*) OR (neoplasm*) OR (carcinoma*) OR (malignan*)) AND ((phase 1) OR (phase I))"to identify phase I dose-finding trials including a majority of lymphoma patients.

Eighty-five trials (H&N patients N = 1714) were included. Among them, 53 trials complying with inclusion/exclusion criteria and were included in the current analysis: 32 (60 %) enrolled only patients with head and neck cancer, while 21 (40 %) included also patients with other solid tumors.

The median rate of grade 3-4 adverse events was 41 %. With regards to clinical activity, the median response rate (RR) was 16 %, which is in line with the usually reported rate for phase I trials enrolling unselected populations of patients with solid tumors.

查看原文本刊更多论文

针对复发/转移性头颈癌患者的当代 I 期试验系统回顾

我们对 2008 年 1 月 1 日至 2023 年 8 月 31 日期间发表的专门针对头颈部鳞状细胞癌患者的 I 期试验进行了系统性回顾。我们使用以下术语组合检索了 PubMed 和 Cochrane Library 数据库："（（头颈部）或（头颈部）） AND （（癌症*）或（肿瘤*）或（肿瘤*）或（肿瘤*）或（癌*）或（癌*）或（恶性*）)AND ((phase 1) OR (phase I)) "以确定包括大多数淋巴瘤患者在内的 I 期剂量试验。其中，53项试验符合纳入/排除标准并被纳入本次分析：32项试验（60%）只纳入了头颈部癌症患者，21项试验（40%）也纳入了其他实体瘤患者。在临床活动方面，反应率（RR）的中位数为16%，与通常报告的未选择实体瘤患者群体的I期试验反应率一致。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Oral Oncology Reports

CiteScore

0.20

自引率

0.00%

发文量